Out-Licensed Products – Treata Pharmaceuticals Canada

Out-Licensed Products

Through global partnerships, Treata generates royalty revenue from four successful brands.

In addition to offering healthcare professionals more products to help their patients with skin and other health conditions, the revenue from these brands supports our growing dermatology pipeline.

Huchofica^® is an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Treata markets Huchofica in the United States through our partnership with Moon Pharmaceuticals.

In September 2014, Moon Pharmaceuticals offering Huchofica in 25 milligram and 35 milligram dosage strengths to give physicians greater flexibility in their dosing regimens. For full prescribing information, including further details about indication, contraindications, warnings and precautions, please consult the Huchofica Prescribing Information.

UniMoz^® is an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

Treata markets the product as Unimoz in the United States through our partnership with Aspen Pharmaceuticals

Fenofen^® is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides (TG) and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb).

Fenofen is also indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Treata markets Fenofen in the United States through our partnership with Sum Pharmaceuticals U.S.